S&P Futures
5,968.75 +10.50 (+0.18%) Dow Futures
43,971.00 +70.00 (+0.16%) Nasdaq Futures
20,944.75 +50.75 (+0.24%) Russell 2000 Futures
2,412.80 +7.00 (+0.29%) Crude Oil
71.20 -0.49 (-0.68%) Gold
2,669.90 -6.40 (-0.24%)
Silexion Therapeutics Corp (SLXN)
After hours:
- ACCESSWIRE
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
GRAND CAYMAN, CAYMAN ISLANDS / ACCESSWIRE / October 9, 2024 / Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its ...
- Business Wire
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
GRAND CAYMAN, Cayman Island, October 01, 2024--Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its extended-release formulation. These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis
